Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
Over the weekend we have seen a rise in the number of cases of Coronavirus, particularly in Italy and South Korea, leading to more disruption to travel and closure of borders. We are now hearing that there have been disruptions to India’s pharmaceutical sector, India is a key player in the export of pharmaceuticals and relies on China for 70% of its raw ingredients. The BIA is continuing to work with innovative organisations across the UK to facilitate the development and scale-up of vaccines.
Posters have been an important factor of the annual bioProcessUK conference for the past few years. These sessions provide the opportunity for early career researchers to showcase their research, as well as themselves, in front of an audience including senior leaders across academic and industrial sectors of the UK bioprocessing community.
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.
In 2020 the BIA is supporting the award winning charity In2scienceUK in their mission to diversify the science sector and give those with the fewest opportunities the chance to gain the experience, confidence, skills and networks to support their future career in science.